Stephen E.F. Spurgeon, M.D.
- Email:
- click here
- Office:
- 503 494-5058
Assistant Professor
Background
Dr. Spurgeon's research focuses on translating lab findings into new therapies in chronic lymphocytic leukemia and lymphoma, particularly mantle cell lymphoma. Dr. Spurgeon has a special interest in: 1) unlocking the importance of cell signaling in lymphoid cancer pathogenesis, 2) identifying new therapeutic targets, 3) developing novel clinical trials, and 4) designing personalized treatment approaches. CLL: Specifically, he is interested in the role of tyrosine kinases and B cell receptor (BCR) mediated signaling in leukemogenesis in chronic lymphocytic leukemia (CLL). He hopes to develop kinase directed treatment approaches for CLL. He also is interested in determining if in vitro kinase targeted drug screens can help predict in vivo response to anti-leukemic therapy. This includes collaborations with Dr. Marc Loriaux, Dr. Jeffrey Tyner and Dr. Brian Druker in the Center for Cell Signaling. Lymphoma: In collaboration with Dr. Craig Okada at OHSU and Dr. Elliot Epner at Penn State, Dr. Spurgeon is exploring the role of epigenetic therapy in B cell malignancies especially in mantle cell lymphoma. Specifically, he is conducting an early phase clinical trial using cladribine, rituximab and vorniostat in relapsed B cell malignancies and newly diagnosed mantle cell lymphoma and CLL. This study evaluates DNA methylation patterns in patients on therapy and hopes to identify important target genes modified by this combination therapy.
Summary of Current Research
Knight Cancer Institute Clinical Research Review Committee (CRRC) Member Guest Lecturer Leukemia and Lymphoma Society Research Interests: Chronic lymphocytic leukemia, indolent lymphoma, intermediate and high-risk lymphoma, B-cell signaling, novel therapeutic targets, clinical trials
Selected Publications
"The selective syk inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemias,"
"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening,"
"Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007,"
"Reversible pulmonary toxicity due to lenalidomide,"
"Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma,"
